How bad­ly does Sanofi chief Paul Hud­son want Prin­cip­ia? Enough to ink a $3.7B buy­out deal, dou­bling down on MS

Sanofi CEO Paul Hud­son has a home for a chunk of that Re­gen­eron mon­ey sit­ting in the bank.

The phar­ma ex­ec is shelling out $100 a share to take out Prin­cip­ia $PRNB — helmed by Mar­tin Babler — and the MS drug that Hud­son has been talk­ing up for months as a break­through in the field. That’s a $3.7 bil­lion deal.

Prin­cip­ia has a whole port­fo­lio of BTK in­hibitors in the pipeline, but it’s ‘168 that is the jew­el in the crown for Hud­son, a part­nered drug which he is now dou­bling down on to help push the “on­go­ing R&D trans­for­ma­tion” at Sanofi. Be­yond MS the brain-pen­e­trat­ing drug has po­ten­tial in oth­er CNS dis­eases, of­fer­ing a po­ten­tial pipeline in a prod­uct.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER